MetaCap

Generate Biomedicines (GENB) vs LB Pharmaceuticals (LBRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LB Pharmaceuticals is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GENB-24.58%LBRX+61.81%
+113%+41%-31%
Feb 27, 20261 yearNov 20, 2026
GENB-24.58%LBRX+61.81%
+112%+40%-31%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GENB versus LBRX key metrics
MetricGENBLBRX
Share price$9.54$38.85
Market cap$1.23B$1.26B
1-day change-8.00%-2.97%
YTD return—+74.53%
1-year return—+153.42%
EPS (TTM)$-2.49$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-25.20M
52-week high$22.67$50.16
52-week low$9.40$15.55
Distance from 52-week high-57.92%-22.55%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+183.02%+49.29%
Average volume1.24M373.16K
Shares outstanding129.10M32.36M
Employees31262
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Generate Biomedicines

GENB stock →

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees

About LB Pharmaceuticals

LBRX stock →

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees

GENB vs LBRX FAQ

Which is bigger, Generate Biomedicines or LB Pharmaceuticals?

LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.26B compared with $1.23B for Generate Biomedicines (GENB).

Are Generate Biomedicines and LB Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons